Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amneal Targets Limited US Ciprodex Pool With FDA Approval

FDA Approval Marks Another Addition To The Firm’s Growing Complex Drug Portfolio

Executive Summary

The FDA has granted approval to Amneal’s ciprofloxacin/dexamethasone otic suspension ANDA product, referencing Ciprodex, adding a further drug to the company’s portfolio as the firm continues its strategic shift to complex generics.

You may also be interested in...

Amneal Generics Unit Continues To Grow Following Complex Products Shift

Amneal’s generics portfolio delivered considerable growth during Q3, as a result of its ongoing shift toward complex products and successful new launches.

Dr Reddy’s Pounces On US Ciprodex Generic As Endo Stumbles

Dr Reddy’s Laboratories has leapfrogged Endo by launching a generic version of of Bayer/Alcon’s Ciprodex (ciprofloxacin/dexamethasone) 0.3%/0.1% otic suspension, as the US firm was stung with a major rejection by the US FDA.

Mallinckrodt Reports 2023 Results After Second Restructuring

Emerging out of its second Chapter 11 bankruptcy filing in the past four years, the company reported a slump in net sales despite positive signals in specific portfolios.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts